CAS 1133432-49-1

GDC 0834

Description:

GDC 0834 is a small molecule inhibitor primarily developed for the treatment of various cancers, particularly those associated with mutations in the Hedgehog signaling pathway. It is classified as a selective antagonist of the Smoothened (SMO) receptor, which plays a crucial role in the Hedgehog signaling cascade that regulates cell growth and differentiation. The inhibition of SMO by GDC 0834 can lead to the suppression of tumor growth in cancers where this pathway is aberrantly activated. The compound is characterized by its specific binding affinity to the target receptor, which allows for a more targeted therapeutic approach with potentially fewer side effects compared to broader-spectrum chemotherapeutics. In preclinical studies, GDC 0834 has shown promise in inhibiting tumor proliferation and inducing apoptosis in cancer cell lines. Its development is part of ongoing research into targeted cancer therapies, aiming to improve treatment outcomes for patients with Hedgehog pathway-related malignancies. As with many investigational drugs, further clinical trials are necessary to fully establish its efficacy and safety profile.

Formula: C₃₃H₃₆N₆O₃S

InChI: InChI=1S/C33H36N6O3S/c1-20-24(9-7-10-25(20)36-31(40)28-18-22-8-5-6-11-27(22)43-28)26-19-39(4)33(42)30(35-26)34-23-14-12-21(13-15-23)29-32(41)38(3)17-16-37(29)2/h7,9-10,12-15,18-19,29H,5-6,8,11,16-17H2,1-4H3,(H,34,35)(H,36,40)/t29-/m1/s1

InChI key: InChIKey=CDOOFZZILLRUQH-GDLZYMKVSA-N

SMILES: CC1=C(C=2N=C(NC3=CC=C(C=C3)[C@@H]4C(=O)N(C)CCN4C)C(=O)N(C)C2)C=CC=C1NC(=O)C5=CC6=C(S5)CCCC6

Synonyms:

• GDC 0834
• N-[3-[6-[[4-[(2R)-1,4-Dimethyl-3-oxo-2-piperazinyl]phenyl]amino]-4,5-dihydro-4-methyl-5-oxo-2-pyrazinyl]-2-methylphenyl]-4,5,6,7-tetrahydrobenzo[b]thiophene-2-carboxamide
• Benzo[b]thiophene-2-carboxamide, N-[3-[6-[[4-[(2R)-1,4-dimethyl-3-oxo-2-piperazinyl]phenyl]amino]-4,5-dihydro-4-methyl-5-oxo-2-pyrazinyl]-2-methylphenyl]-4,5,6,7-tetrahydro-

(R)-N-(3-(6-((4-(1,4-Dimethyl-3-oxopiperazin-2-yl)phenyl)amino)-4-methyl-5-oxo-4,5-dihydropyrazin-2-yl)-2-methylphenyl)-4,5,6,7-tetrahydrobenzo[b]thiophene-2-carboxamide

CAS: 1133432-49-1

(R)-N-(3-(6-((4-(1,4-Dimethyl-3-oxopiperazin-2-yl)phenyl)amino)-4-methyl-5-oxo-4,5-dihydropyrazin-2-yl)-2-methylphenyl)-4,5,6,7-tetrahydrobenzo[b]thiophene-2-carboxamide

Purity: 98%

Molecular weight: 596.76g/mol

Ref: 54-OR1066076

GDC-0834

CAS: 1133432-49-1

GDC-0834 inhibits BTK with an in vitro IC50 of 5.9 and 6.4 nM in biochemical and cellular assays, respectively, and in vivo IC50 of 1.1 and 5.6 μM in mouse and

Formula: C₃₃H₃₆N₆O₃S

Color and Shape: Solid

Molecular weight: 596.74

Ref: TM-T11379

GDC-0834

CAS: 1133432-49-1

GDC-0834 is an irreversible inhibitor of the enzyme tyrosine protein kinase. It has a pharmacokinetic profile that is similar to radiation and can be used as a replacement for radiation therapy. GDC-0834 selectively targets human liver, lung, and kidney cells, which are indicated by increased levels of apoptosis in these tissues. The molecule also inhibits the proliferation of hematopoietic cells, possibly due to its ability to cause mitochondrial membrane depolarization. GDC-0834 has been shown to have therapeutic efficacy against autoimmune diseases such as rheumatoid arthritis and psoriasis.

Formula: C₃₃H₃₆N₆O₃S

Purity: Min. 95%

Molecular weight: 596.74 g/mol

Ref: 3D-IVB43249